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Simple Summary: Biochemical inhibition of male sex hormone function (androgen signaling), also
known as androgen deprivation therapy (ADT), for human prostate cancer remains a major treatment
strategy almost 80 years after the discovery of androgens as a major factor in the disease. Drug
development has resulted in an increasing potency, whereas the understanding of the consequences
of these new-generation inhibitors in cancer survivors for increased periods of time, and indeed
for their individual cancer cells, has lagged behind. Drugs are still tested in laboratory cell systems
developed 40 years ago, which indicate a toxic effect of the antiandrogens on the tumor cells, not
matched by direct studies of human tissues. In this review, I discuss the limits of our understanding
of both how these drugs work and potential side effects, which are often overlooked in the face of a
perceived urgency to get better inhibitors in to the clinic.
Abstract: Increasingly sophisticated therapies for chemical castration dominate first-line treatments
for locally advanced prostate cancer. However, androgen deprivation therapy (ADT) offers little
prospect of a cure, as resistant tumors emerge rather rapidly, normally within 30 months. Cells have
multiple mechanisms of resistance to even the most sophisticated drug regimes, and both tumor
cell heterogeneity in prostate cancer and the multiple salvage pathways result in castration-resistant
disease related genetically to the original hormone-naive cancer. The timing and mechanisms of
cell death after ADT for prostate cancer are not well understood, and off-target effects after long-
term ADT due to functional extra-prostatic expression of the androgen receptor protein are now
increasingly being recorded. Our knowledge of how these widely used treatments fail at a biological
level in patients is deficient. In this review, I will discuss whether there are pre-existing drug-resistant
cells in a tumor mass, or whether resistance is induced/selected by the ADT. Equally, what is the cell
of origin of this resistance, and does it differ from the treatment-naïve tumor cells by differentiation or
dedifferentiation? Conflicting evidence also emerges from studies in the range of biological systems
and species employed to answer this key question. It is only by improving our understanding of this
aspect of treatment and not simply devising another new means of androgen inhibition that we can
improve patient outcomes.
Keywords: prostate cancer; androgens; androgen deprivation therapy: tumor resistance; model systems
1. Introduction
Treatment protocols for prostate cancers have developed in the years since the Nobel
prize was awarded to Charles Huggins in 1966 for the demonstration that hormone manipu-
lation via orchidectomy results in the remission of hormone-sensitive prostate cancer [1]. The
current use of chemical castration agents is more acceptable than surgery to most patients,
and the pharmaceutical industry has invested considerably in the development of various
generations of these drugs, such as enzalutamide and darolutamide (Figure 1). These drugs
are powerful inhibitors which bind with differing affinities to the androgen receptor protein
and their clinical application is constantly being reviewed. The structure of androgen response
inhibitors originally mimicked testosterone (steroidal antiandrogens), but current nonsteroidal
antiandrogens are molecularly optimized for maximal inhibitory effects.
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Improvements in the drugs’ affinities for the Androgen Receptor (AR) target
(Figure 1) and the structural chemistry/molecular fitting approaches used for their develop-
ment have resulted in improved biochemical properties in cell culture testing. However, the
mean time from Androgen Deprivation Therapy (ADT) treatment start to relapse (assessed
using increase in serum Prostate-Specific Antigen (PSA) levels) remains around 30 months
for patients without metastases and half that for patients with metastases [2]. There is also
some evidence that very high initial Gleason scores (9/10) of cancer progress more rapidly
to castration-resistant disease after ADT than on placebo [3].
 
Figure 1. The evolution of direct (nonsteroidal) inhibitors of the androgen receptor. The increase in affinity of the drugs for
the receptor with structural engineering is striking [4]. Note also that darolutamide is stated not to cross the blood–brain
barrier, unlike the other molecules, and ralaniten binds to a different part (the flexible portion of the Androgen Receptor
(AR) molecule, so a comparable IC50 is not appropriate. Ralaniten has recently been withdrawn due to low clinical efficacy,
despite promising preclinical data).
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1.1. Androgen-Based Therapies Retain Activity after Failure of First-Line AR-Based Treatments
After the failure of first-line androgen deprivation therapy (ADT), such as luteiniz-
ing hormone-releasing hormone (LHRH) antagonists and bicalutamide, next-generation
hormone-based therapies such as abiraterone can alter the intratumoral androgen
production [5] that is observed in castration-resistant prostate cancer (CRPC) or
enzalutamide [6] and apalutamide [7] can suppress residual androgen responses in CRPC [6].
After the (almost inevitable) failure of even the latter androgen-based treatments [8], less
specific, replication-based, more toxic chemotherapies such taxane treatments are applied
for castration-resistant prostate cancers. Some hope of further specific chemotherapies,
such as olaparib, which target the proportion of prostate cancers with DNA damage repair
defects recently showed promise in clinical trials [9]. At this point, the oncologist can
do little beyond palliation to mitigate the development of the most fatal form of disease,
with a poorly differentiated histology, typical of the higher Gleason grades. The advanced
CRPC lesions display a basaloid or neuroendocrine phenotype (neuroendocrine prostate
cancer—NEPC) and ultimately have a poor prognosis [10].
1.2. Combination Therapies Which Include Androgen Blockades Can Extend Patient Survival
Combination therapies, featuring both taxanes and androgen signaling inhibition, are
improving survival in newly diagnosed patients with high-grade metastatic disease [11].
However, other novel immunotherapies have, to date, failed to show the same promise
in prostate cancer treatment, with efficacy only in a minor population of patients [12],
unlike the large-scale remissions seen in melanoma, small cell lung cancer, and some
leukemias [13].
1.3. Androgen Blockade: A Time-Limited Treatment?
Nevertheless, ADT remains the mainstay of primary drug treatment for PCa. A patient
selected for hormone therapy will normally derive benefits for 1–4 years, although in a
small minority of patients, the remission can last for up to 10 years. The future of ADT
seems to lie with the generation of new and improved androgen signaling inhibitors
(Figure 1) [4], despite the expense incurred by both the pharmaceutical industry and the
inevitable extra costs to healthcare systems. Combination treatments, and various total
androgen blockades—both constant and intermittent [14]—have all been tested in clinical
trials. However, the cancer returns despite apparent increased survival in intermittently
treated populations [15], a therapeutic strategy that is probably underused. If the tumor
cells are indeed dependent on androgens, even in CRPC [16], then why a cocktail of
inhibitors of androgen signaling does not inevitably result in increased remission or even a
cure is unclear.
The use of new androgen receptor inhibitor strategies is probably also fueled by the
size of the worldwide markets, which was USD 7 billion in 2019 (according to alliedmar-
ketresearch.com). This market is set to increase by a rate of >10% every year, driven by a
combination of increasing patient numbers in the Western world and improved healthcare
in countries where prostate cancer in elderly males was once a minor disease, due to
historically shorter life spans as a result of mainly infectious diseases.
In this review, I consider the biochemical and biological mechanisms of resistance,
both obvious and more esoteric, in order to open a debate about how to optimize the
application of the current best, but nevertheless time-limited, therapeutic strategy. I will
examine the limits of our knowledge, focusing on the biological and molecular responses
to prostate cancer treatments, which primarily inhibit the response to androgen.
2. Targeting the Androgen Signaling Pathway
The inherent complexity and multistep nature of the androgen response pathway, and
the tissue-specific molecules involved (Figure 2), show that this signaling pathway is an
ideal therapeutic target, but increasing identification of functional androgen receptor (AR)
expression in non-prostate tissues (see below, 10.2) could mitigate the utility of targeting
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this pathway. The cellular processes involved in the androgen response cascade that are
targetable can be broken down into discrete therapeutic intervention points:
• Extracellular provision of testosterone;
• Activation of testosterone by 5α reductase to dihydrotestosterone (DHT);
• Androgen metabolism and receptor engagement in the cell cytoplasm;
• Turnover and metabolism of the AR and co-activator proteins;
• Transcription complex formation and activation of gene expression in the cell nucleus;











Figure 2. The androgen signaling cascade in prostate epithelial cells.
A schematic view of the various therapeutic interventions that are currently employed
is shown below (Figure 3). The molecular strategies can be divided into three main
categories:
• Direct binding inhibitors of the AR;
• Testosterone activating 5α- reductase inhibitors and
• Intratumoral and extratumoral testosterone inhibitors.
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Figure 3. Known therapeutic interventions to block androgen signaling. Specific inhibitors shown in red. Blue boxes
correspond to headline strategies in Table 1. HSP: Heat Shock Proteins, LHRH: Luteinizing hormone-releasing hormone,
Cyp17: Cytochrome P450 17α−hydroxy/17,20-lyase, AR: Androgen Receptor, PSA: Prostate Specific Antigen, DHT:
Dihydrotestosterone, CRPC: Castration Resistant Prostate Cancer.
Chemical inhibition has been achieved with a high degree of specificity and the biochem-
ical consequences of these interventions have been described in detail elsewhere [17,18] and
the referencing in Table 1.
Table 1. Androgen receptor signaling by conventional and alternate mechanisms can be inhibited by specific small-molecule
inhibition.









AR gene amplification to utilize
low intratumoral androgens
[19–21]
Androgen synthesis Intratumoral CYP17 Abiraterone




dihydrotestosterone (DHT) Steroid 5-alpha reductase Dutasteride/Finasteride
Switch in 5aR isotype or use of
testosterone/adrenal androgens
[25,26]
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Table 1. Cont.
Drug Class Molecular Target Drug Example Escape Mechanism Ref.
Androgen Receptor (AR)
inhibitor






Gain of function mutations in
the androgen receptor gene to
enable it to use other steroid
hormones.




Dimerization of AR Androgen receptor Stilbene, Resveratrol







AR S81: CDK1, CDK5 and
CDK9















Expression of AR splice variants
which translocate to the nucleus
in the absence of androgen.
[38,39]
Binding of nuclear
androgen receptor to: (1)









Changes in balance between AR
co-activator and co-repressor
molecules and relative affinity of
the receptor by mutation of AR.
[40–42]
Downstream effects of





Activation of alternative salvage
















Redundancy in the heat-shock
chaperone system
Inhibition of AR proteolysis
[47–51]
The data in the table are not intended as an exhaustive list but are an illustration of the many escape mechanisms available to a prostate
cancer cell from ADT.
2.1. Resistance to Androgen Blockade
The multiple alternative signaling mechanisms present in the AR-expressing cells
is increasingly apparent. These mechanisms enable escape from ADT and maintenance
of AR signaling in both normal and malignant cells (Table 1). For example, inhibition
of androgen synthesis by gosrelin or abiraterone can be circumvented by intratumoral
androgen synthesis and AR expression amplification or via the glucocorticoid receptor
and glucocorticoids, respectively [19–24]. In evolutionary terms, the escape, salvage
and/or backup signaling pathways are a useful resource for an affected cell, enabling
the persistence of survival and proliferative signals in the absence of the principal ligand
response. For a mammalian population, loss of androgen signaling would have extreme
effects on fertility and reproduction, providing a strong evolutionary driving force for the
presence of alternative salvage pathways.
2.2. Targeting Alternative Pathways
In prostate cancer, a known number of alternative AR activation pathways exist,
driven by cytokines and growth factors (Table 1 and Figure 4). In particular, the IL6
pathway has been a target for inhibitor trials, which were originally developed to target
inflammatory responses. However, trials in prostate cancer did not result in considerable
survival advantages, despite promising results in the initial phases [52,53]. Signaling via
epidermal growth factor and insulin-like growth factor has also been shown to activate
AR signaling [54], but the ubiquity of these pathways in normal tissue function probably
means that the risks of adverse (and long-term) effects through targeting them are high.
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As the alternative pathways do not exploit particular gene mutations, they should pre-exist
in androgen receptor inhibitor treatments and are almost certainly active in a number of
other cell types that either lack exposure to circulating androgens or some of the other
intermediate signaling molecules such as 5α reductase (Figure 3). Many of the growth-
factor-stimulated pathways are constitutively activated by paracrine or autocrine secretion
of and response to growth factors (such as TGFβ) either in tumor cells or in the contributing
cells in the tumor microenvironment (for example, stromal and hematopoietic cells) [55,56].
TGFβ can have acutely toxic short-term effects on BPH1 cells [55], and persistent exposure
to TGFβ has been shown to promote and increase tumorigenic properties, including
epithelial to mesenchymal transition (EMT), in breast progenitor cells [57]. Most prostate
tumor models used for therapeutic development both in vitro and in vivo (which were
initially selected purely for their abilities to grow quickly) do not share the activation







Figure 4. Alternative growth factor driven signaling pathways after androgen blockade. Canonical androgen response is
shown on the right of the figure (as in Figure 3), whereas under conditions of limiting androgens or ADT, at least three
alternative pathways can be activated, all resulting in steroid-independent activation of AR signaling: (i) Epidermal Growth
Factor and Insulin-Like Growth Factor (EGF/IGF) stimulated signalling via Phosphatidylinositol 3-kinase (PI3K), Protein
kinase B ( Akt/PKB) and mediated by phosphatidylinositol 3,4,5-triphosphate (PIP3) and Phosphatase and tensin homolog
(PTEN) levels in cells. (ii) Signalling with the ras proto-oncogene (ras signalling) via Activated Cdc42-associated kinase
(Ack), The Ras/Raf/Mitogen-activated protein kinase/ERK kinase (MEK) pathway and the Proto-oncogene tyrosine-protein
kinase Src (Src), and (iii) Interleukin 6 (IL6) cytokine signalling which activartes AR via janus kinase-signal transducer and
activator of transcription (JAK1), signal transducer and activator of transcription 3 (STAT3) and histone acetyltransferase
p300 (p300) intermediates as shown.
The list of potential resistance mechanisms to ADT is long (Table 1) and ubiquitous
for all proposed therapeutic strategies. Although some of these are druggable, there is a
fundamental gap in our knowledge of when and how to anticipate resistance mechanisms.
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Again, the existence of a mechanism in vitro does not necessarily mean that it is func-
tional in vivo. For example, a tumor consisting of several million cells could contain rare
pre-existing cells that have activated drug resistance towards the development of CRPC
(intrinsic resistance). Presumably, the larger the tumor size, or perhaps the existence of de-
fects in DNA repair mechanisms, would increase the presence of such pre-existing resistant
tumor clones. Does such increased tumor cell heterogeneity provide an explanation for the
recently described differences in the efficacy of ADT in higher Gleason grade cancers [3]?
Furthermore, tumor cells could undergo trans-differentiation or mutation in response to
the treatment (induced resistance). This will be discussed in more detail below. Clearly,
a successful treatment strategy should block the resistance mechanisms, but the method
employed depends critically on which mechanism the tumor cell uses to escape ADT.
Novel resistance mechanisms are being uncovered with increased frequency as next-
generation antiandrogen treatment fails [58,59]. In addition to the established ADT re-
sistance mechanisms, such as AR gene amplification and splice variants, amplification
of an AR transcriptional enhancer has been discovered which boosts the activation of
AR-regulated genes even in the presence of ADT [31].
Metabolic changes in cells, such as increased and altered lipid usage, may also play a
role in CRPC development [60], and redifferentiation or trans-differentiation of tumour
cells to different cell types, such as cells with a gastrointestinal phenotype with a primitive
stem-like transcriptome [61,62], has been observed. Increased expression of stem and
embryonic master regulators [63] such as NOTCH [64] and WNT [65] has been reported
in CRPC tissues after enzalutamide treatment, but this effect could be a post-treatment
regenerative response rather than a true adaptation.
With so many known alternative pathways available to a prostate cancer cell seeking
to bypass drug treatments, the time-limited responses to ADT based on AR signaling
inhibitors is perhaps not surprising. Multiple redundancies of these salvage or alternative
pathways also compounds the difficulty of achieving truly global inhibition of AR function
by combinatorial therapy. In almost all situations, a resistant clone will emerge from a
treated tumor mass if the adapted cells have a growth or survival advantage. The ideal
life-extending combination treatment should therefore anticipate resistance, rather than be
administered when the resistant cell type has emerged and could further adapt. Only a
few early biomarkers of the emergence of resistance have been discovered (see Section
4) to guide such an anticipatory blockade and there is no certainty that several escape
mechanisms are simultaneously employed in the treated tumor mass, with one likely to
predominate, given the heterogeneity seen in patient studies.
3. Mechanisms of Cell Death after Application of Androgen Signaling Blockade
As the aim of ADT is to eliminate prostate cancers in man, it is important to know the
precise mechanism of cell death induced by the drugs, if we wish to overcome resistance.
Even after the length of time since the therapy was first applied clinically, the death
mechanism remains unclear and is defined by the experimental model used for study.
For example, does castration by surgical or chemical means actually induce cell death by
apoptosis, or is the effect more passive: either senescence or atrophy?
3.1. The LNCaP Cell Line: Industry Standard Sndrogen-Responsive PCa Cell Model
Until fairly recently, the industry standard cell for ADT drug development was al-
most exclusively the LNCaP fast-growing clone (LNCaP-FGC), originally reported over
30 years ago [66]. The patient origin of the LNCaP cell lines is often misunderstood to be a
well-differentiated cancer model for ADT. However, according to Horoszewicz et al., [66],
“The patient was a 50-year old male with stage D1 prostate cancer. He was originally
treated with oral estrogens, but 6 months later, bony metastases were detected. The patient
was randomized and treated with methyl CCNU (a chemical carcinogen) and Estracyt
(a dual estrogen and nitrogen mustard chemotherapy). One month later a supraclavicular
lymph node was palpated and a needle aspiration confirmed the diagnosis of metastatic
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carcinoma. It was from this biopsy that the LNCaP culture was initiated”. Subsequently,
a mutation (Codon 877 Thr to Ala) in the AR gene [67], which perhaps unsurprisingly,
given the treatment regime, renders the LNCaP cells susceptible to growth stimulation by
estrogens, was found [68]. The karyotype of the LNCaP cells is highly aneuploid, more
reminiscent of CRPC than that of a primary cancer still treatable with androgen receptor
inhibitors (2790 exome mutations in LNCaP vs. 16–33 in primary cancer hormone-naïve
biopsy exomes) [69]. Intriguingly, LNCaP contained multiple X chromosomes (the gene
locus for AR) in the original cell line [70], but a recent re-quantification of the AR copy
number in LNCaP by my own laboratory has confirmed the single, mutated copy in the
current ATCC reference culture. The CRPC characteristics of LNCaP were also reflected
in the undifferentiated non-glandular tumor histology, both in man but also in the nude
mouse xenograft tumors which appeared 16 weeks after inoculation of 107 original LNCaP
cells and were serially transplantable. Despite the origin in a metastatic lesion, LNCaP
are only modestly invasive into local muscle from a subcutaneous graft [66]. Most studies
confirm that LNCaP growth responds positively, if modestly, compared to its responsive-
ness to epidermal growth factor, to medium supplementation by dihydrotestosterone or
estrogen [71], and its growth is inhibited by AR inhibitors such as bicalutamide [72]. The
cells do express prodigious amounts of prostatic acid phosphatase and PSA, however, as
evidence of positive AR signaling.
3.2. Cell Death in Cell Line Models of PCa after Androgen Signaling Blockade
Published evidence for increased cell death due to apoptosis after ADT by bicalu-
tamide treatment is more modest. In one study, there was no increase in cleaved PARP,
Caspase 3/7 or 8 after monotherapy of both LNCaP and 22RV1 cells with 10 micromolar
bicalutamide [73]. In contrast, extensive treatment with 100 micromolar bicalutamide [74]
did provide evidence of apoptotic death after 24–48 h treatment. However, the latter result,
with the requirement for such a high concentration of bicalutamide, may be of limited
relevance to a clinical treatment. It seems more likely that androgens protect LNCaP cells
against their naturally high levels of apoptotic cell death (around 15% in any population—Dr
M Sharrard, personal communication) and that inhibition of signaling merely restores this.
One study of natural, rather than chemical, AR inhibition by culturing LNCaP cells under
androgen-free conditions in vitro, and in both patient material and LNCaP xenografts
in vivo, strongly suggested irreversible senescence rather than apoptotic cell death [73] as
the mechanism for cell losses after castration. LNCaP cell cycle arrest, senescence and atro-
phy in response to bicalutamide, but not to the earlier steroidal anti-androgen flutamide, is
more commonly reported [75]. In a further in vitro/in vivo study with the LNCaP model,
treatment with Casodex or enzalutamide seemed to only slow cell growth and suppress
PSA expression, but paradoxically resulted in more metastases [76] from xenografts in
immunocompromised mice.
Given the difficulties of working with an industry standard cell line, which carries a
mutated AR target gene, a number of investigators transfected new copies of wild-type
AR into LNCaP [77]. These exogenous AR copies are not under normal cellular expression
control, and expression is frequently driven by strong heterologous promoters, which do
not display the self-regulatory nature of the human AR transcriptional control sequences.
However, the synthetic cells (termed generically LNCaP/AR) were ultra-responsive to the
addition of DHT, as judged by PSA production, and have been used in the biological testing
of the next-generation drugs such as enzalutamide [78,79]. More recently, the LNCaP/AR
cells were used to elucidate the mechanism by which SOX2 overexpression influences
resistance to enzalutamide [80], which was developed after analyses of human tissues and
in a mouse prostate knockout model [81]. An observed lineage plasticity, and requirement
to lose or inactivate tp53 and pRb1, was common between the models, resulting in a
basal/NE-like resistant cell type in which inhibition of the master transcriptional controller
EZH2 restored sensitivity to ADT. However, derivation of enzalutamide-resistant cells
from four different prostate cancer cell lines (including LNCaP but not LNCaP/AR) was
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unable to replicate the SOX2-based mechanism [82]. These ENZAr cells also failed to show
an increased growth dependence on glucocorticoids [82], previously reported to be another
primary resistance mechanism [83]. There are further multiple reports of NE-like cells after
serum starvation [84] or epigenetic manipulation of LNCaP [85] —in the absence of any
ADT/enzalutamide treatments.
We and others have proposed the existence of low/no PSA expressing cancer cells
with an aberrant basal phenotype [86,87] both in vitro and, perhaps more importantly, in
cells freshly extracted from human prostate cancers [88]. Their cancer origins are defined
by the presence of changes to PTEN status [89], overexpression of c-myc, the presence
and expression of TMPRSS2-ERG fusion genes [90] and a cancer-like CpG methylation
profile [91]. These cells are naturally unresponsive to the blockade of androgen signaling
and would provide a reservoir of resistant cells which produce tumor-regenerating cells
either by the acquisition of inactivating mutations or at the cessation of the AR inhibitory
treatment.
Does this range of responses reflect the sustained ability of the LNCaP model to
(i) establish in culture from an original xenograft, (ii) an ability to survive changes in
laboratory culture conditions or (iii) the development of a “convenient” fast-growing
laboratory clone? When one now considers the history of LNCaP—40 years of culture
(since 1978) initially in growth medium containing 15% FCS, selection for a fast growing
clone, changes in karyotype (4 X chromosomes in 1979; now, only one AR copy in the
FGC clone) a median chromosomal number of 85-89 and an extreme phenotypic plasticity
based on culture conditions [70,85,92]—LNCaP does allow the study of AR gene regulation,
but is it still the ideal model (in 2020) on which to base studies of the precise molecular
mechanisms of prostate cancer AR response and treatment resistance?
3.3. Cell Death in Animal Models of PCa after Androgen Signaling Blockade
In animal models, the first biological evidence for prostate cell death after castration
came from the response of normal tissue to surgical castration [93], where the rat prostate
rapidly involutes, and both morphological and molecular evidence of apoptosis was
evident. In a follow-on from this work, the same techniques plus a determination of
specific gene expression changes (to TGF beta, TRPM2 and calcium signaling) were shown
in xenografts of the androgen-sensitive human PC82 cancer xenograft. In this model, the
peak of apoptotic signaling was achieved after 72 hours, accompanied by tumor cell death,
and a 70-fold decrease in Ki67 staining, indicative of a complete blockade of cell replication,
was noted [94].
In direct contrast, a similar study in rats, using the highly differentiated Dunning
R3327PAP tumor, detected no rapid reduction in tumor cell number at 3, 7 and 14 days post-
surgical castration [95]. The Dunning system of rat tumors has been exploited for many
years since its development [96]. Whilst it offers an in vitro/in vivo shuttling experimental
model with a wide range of responses to androgens and castration [97], its relevance to
human disease is probably limited by the low homology between rodent and human
prostates, both morphologically and in the effective concentration of androgens circulating
in the experimental animals—all of which contribute to the inability of the Dunning tumors
to secrete recognized human prostate cancer markers [98].
In the Dunning R3327PAP cancer cells, whilst the mitotic index was reduced after
castration, no morphological or molecular evidence of apoptosis was seen. However,
similar apoptotic cell death to that seen in normal rat prostate was seen in the adjacent
normal prostate [95].
3.4. Cell Death in Human Tissues after Androgen Signaling Blockade
In human tissue, there seem to be major differences in castration responses compared
to the experimental animal and cell line studies. Murphy et al. [99] examined the mor-
phological consequences of ADT (leuprolide +/– flutamide) in 12 sequentially sampled
patients. After 2–14 months (median 3–4 months) of treatment, neither degeneration nor
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necrosis in the neoplastic prostate glands but an increase in the inter-glandular stromal cells
was seen, and the authors hypothesized that the effect of ADT was to arrest tumor growth,
rather than induction of apoptotic or any other mechanism of cell death. Interestingly, they
noted that ADT affected only certain cell populations within the cancer mass, unlike the
response of the more homogeneous PC82 human PCa xenograft, where widespread cell
death was observed [94]. Whilst serum PSA was essentially zero in these ADT-treated
patients, a persistent PSA protein signal in the prostate tissues was observed.
A larger study using 18 patients 3 months after castration [100] observed some apop-
totic cell death, mostly in the lowest grade tumors (probably now reclassified as abnormal
rather than cancerous under the amended Gleason grading system [101]), but reported that
the majority of patients showed (as in Murphy et al. [99]) both tumor cell atrophy and a
decreased proliferation rate. It should be recalled that at 3 months post-castration, PSA
levels in patients have probably only decreased by around 30%, at a time point long after
that used in the animal xenograft studies (Section 3.3).
In conclusion, the many cell line studies (including those in the industry standard
LNCaP cells and variants thereof) promote the case for an active cell death based on
apoptosis, either in vitro or in xenografts. This certainly looks to be the case in normal
human tissues, but no such effect is seen in human cancers. The expansion of human
stroma is intriguing and demonstrates the importance of considering the entire prostate
response to castration, rather than the convenience of fast-growing cell lines.
4. Gene Expression Changes in Prostate Epithelial Cells during the Application of an
Androgen Signaling Blockade in Patients
The human tissue data for cell death are therefore both incomplete and inconsistent
with the simplified view provided by the cell line and animal model systems. Since it
is the human disease which should drive treatment strategies, a number of studies have
approached mechanisms of tumor death by studying gene expression in directly biopsied
human tissues. The timing of the various studies with respect to treatment initiation are
extremely variable and are summarized in Figure 5. Androgen-based therapies (ADT) do
have remarkable effects on prostate cancer growth and progression. However, it has also
been shown that the AR-stimulated transcriptome in cancer cells is quite distinct from that
in non-malignant cells [102], which complicates any study of unfractionated human tissue
where normal cells frequently coexist.
To monitor the effects of ADT in patients, prostate-specific antigen (PSA) remains
an excellent biomarker of AR activity in both normal and malignant cells [103]. As a
biomarker of cancer treatment in man, a 30% decrease in PSA expression is seen after
3 months androgen blockade and an absolute PSA nadir at 7–8 months [104]. This is
not comparable to the effects of a strong cytotoxic drug in rapidly growing cells, where
evidence of immediate cell death and tumor shrinkage (within 72 hours) can normally be
seen—the time point used in many of the cell line model studies. However, remarkably
little is known about the biology and genetics of the treatment in man, beyond its effects
on PSA.
4.1. The Dynamic Changes in Gene Expression after ADT in Human Tissues
In early gene-specific studies (Figure 5 and Table 2), designed to test a specific hy-
pothesis, Kruithof-Dekker et al. [105] showed by immunohistochemistry that there was
a surge in the expression of estrogen receptor (ER alpha) after 3 months of treatment
with etylamide + flutamide (the equivalent of total androgen blockade in 1996). More re-
cently, Al-Ubaid et al. [106] detected an upregulation of the DNA repair protein Ku70 after
32 months ADT using leuprolerin, perhaps implicating DNA damage responses as part of
the ADT effect on target cancer cells [107]. The two processes are increasingly associated,
given the successful clinical use of poly ADP-ribose polymerase-1 (PARP) inhibitors as
prostate cancer therapies [108], but in the subset of patients with DNA repair deficiencies.
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Figure 5. Gene expression studies after androgen blockade in prostate tissues. The total numbers of up and downregulated
genes after ADT are shown in green and red, respectively, in Table 2.
Table 2. Gene expression studies in human tissues after ADT.
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* Upregulated genes shown in green, downregulated in red. The only gene significantly upregulated in all 3 ‘total genome’ transcription
studies was the retinoic acid responder 1 gene (RARRES1).
A better examination of the genetic consequences of ADT comes from studies of whole
genome transcriptomes, initially by Holzbeierlein et al. [109] (goserelin + flutamide) and
updated by Lehmusvaara et al. [110] (goserelin + bicalutamide). Both studies used patient
tissues biopsied after 3 months of treatment. The expression changes gave no indication
of the mechanisms of cell death, which surely should have been apparent at a time point
when PSA levels were falling in the patients.
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A common restriction in such gene expression studies (of mRNA) is the timing of the
studies. Biological effects are frequently preceded by changes in mRNA expression over
hours or even days. For this reason, a more recent study by Shaw et al. [111], which was
carried out on patient biopsies after 7 days of deregalix treatment, could have provided
more informative data about the primary tissue responses to ADT. Whilst no evidence
of a cell death mechanism was again evident, a strong upregulation of estrogen receptor
was seen, but localized to the stromal cells, rather than epithelial cells. This was in
broad agreement with the (3 month) ADT immunohistochemical studies of Kruithof-
Dekker et al. [105]. However, the two studies differed in the cellular location of any
epithelial ESR expression; whereas the earlier IHC showed expression in sporadic basal
cells, Shaw et al. [111] found expression in luminal (AR+) cancer cells.
Despite remarkably similar working protocols, the total gene expression studies re-
vealed only a few genes whose expression was commonly altered in all of the studies.
There were irregular increases in the expression of a number of genes implicated in al-
ternative AR stimulation pathways, such as IL6 [112], but also other genes which mark
stem-like and amplifying normal cells in the prostate, such as SMARCD [113], ALDH [114]
and ETS2 [115]. However, the only gene whose expression was increased in all three
transcriptional studies was retinoic acid responder 1 gene (RARRES1)—a known tumor
suppressor gene in prostate [116], whose expression is positively regulated by retinoic
acid in differentiating normal skin epithelium [117]. My own laboratory has identified
RARRES1 as a transcript repressed in the tumor-initiating population of prostate epithelial
cells but upregulated in the tissue, restoring the population of (normal) basal transit ampli-
fying cells [88,118]. Thus, the expression signature for ADT-treated prostate tissues (from
all three studies) at 3 months after treatment initiation probably reveals not a cell death
profile but rather a very rapid increase in tissue repair, initiated by a normal basal cell
population and probably regulated by retinoids. In both the Prostate Cancer Prevention
Trial (PCPT) [119] and in a meta-analysis of 15 other studies [120], there was a positive
correlation between serum retinoid levels and poor survival in prostate cancers. An orphan
retinoic acid receptor (RORgamma) can also drive the AR response program in the absence
of AR or its ligand in CRPC [121]. Whilst a regenerative RA response is marked strongly
by RARRES1 upregulation, regrowth of the tumour component is less likely to be marked
by increased RARRES1 expression, due to the uniformly low levels of RARRES1 detectable
in most cancer cell types, including prostate [116,118].
A more recent update of the responses to androgen blockade, left as an imprint in the
circulating tumor cells (CTCs) from patients, was revealed by a single cell RNA sequencing
study of CTCs from 13 patients [122], although the intact cell numbers studied were low
(77) since most such CTCs are probably inviable or undergoing apoptosis. Such a focused
study of persistent changes could also alter our thinking about the nature of CRPC in
man. The data emphasized the importance of alternative splicing of the AR to yield a
ligand-independent activation [123] but also revealed a lower than expected frequency
of changes in expression and mutation of the glucocorticoid receptor gene, previously
reported to be a primary mechanism of enzalutamide resistance [83]. Therefore, either the
CRPC CTCs are a different tumor subclone to that seen in biopsy material and in mouse
xenografts [124], or we are dealing with an evolving cell type in man (as shown in below).
4.2. The Dynamic Changes in Gene Expression after Castration in Mouse Tissues
To better model the effects of castration, animal models allow the sequential sampling
which is not possible in human patients. Accordingly, the indeterminate cell types, which
expressed the genes showing expression changes in the human experiments, can be re-
solved by unbiased single-cell RNA sequencing and cluster analysis to identify specific cell
types. Recently, Karthaus et al. [125] reported such a single-cell RNA sequencing analysis
to identify cellular subpopulations in mouse prostate. They were able to identify three
different luminal populations, as well as a basal population. When the mice were castrated,
a proportion of the luminal cells survived and were responsible for prostate regeneration
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(a rapid event in mouse prostate). RNA signature comparisons with human prostate
samples identified a number of similarities, but not identity between the murine luminal
cells and human luminal epithelium. All of the biology was carried out on mouse systems,
and functional associations to man were drawn by comparisons of similarity. Conclusions
about prostate regeneration after ADT were made on the same basis. However, this study
provides a real indication that we now have the means to answer the key questions about
the mechanism of ADT (and resistance development).
The currently published evidence does not yet give a clear picture, even when studying
gene expression changes in human tissues. Perhaps significantly, no evidence of cell death
gene expression was seen at a time when serum PSA levels are falling in patients, but
rather the activated genes indicate either a persistence of unaffected tissue or even tissue
regeneration.
5. Modeling Resistance to Androgen Blockade: The Quest for a Defining Mechanism
The main issues with the study of tumor resistance (in man) will probably only be
resolved by analysis of multiple biopsies taken before, during and after ADT relapse. Many
patients are unwilling to be subjected to biopsy while in remission, so most studies are
again carried out in cell lines and animal models—or as end point data in relapse/autopsy
(after perhaps several months or years of treatment). Should such biopsies be obtained,
the choice of biopsy site in a late-stage, highly heterogeneous population of tumors could
be compromised by the genetic heterogeneity and lack of a known tumor development
lineage [126]. Thus, unbiased single-cell sequencing [125] should be the method of choice,
were the clinical material made available. It is also important at this stage to recall the
caveats previously discussed concerning mechanisms of responses in the various model
systems when examining the nature of relapse from ADT.
5.1. Cell Line Studies of the ADT Resistant State
Most established cell lines can be manipulated to ADT resistance—for example, by
culture of LNCaP for up to 12 months in increasing concentrations of enzalutamide to
generate EnzaR cells for further study, which mimics the extended exposure times of ADT
patients in vivo, and the selective pressure to develop such resistant cells. The molecular
basis of resistance is nevertheless complex, involving both changes to the AR gene (which
are extensively discussed elsewhere [28,29,126–129] and were summarized in Table 1).
Some of these molecular mechanisms are perhaps not unexpected, if the nature of the
androgen signaling pathway is taken into account. There are three possible outcomes of
such pathway manipulation. Firstly, the removal of exogenous androgens by LHRH pre-
vents the flow of substrate (hormone) into the pathway. The system can react by activating
new and endogenous means of synthesizing substrate (androgens) to compensate [130].
When the response pathway is inhibited (as desired), it also reacts by providing a greater
pool of the receptor to react with as much of the ligand which is remaining. This can occur
at several levels: (i) simple overexpression of the AR gene [31,131]—a more reversible
response to the changing microenvironment, (ii) alternative splicing of the AR mRNA
to generate a truncated protein which can translocate to the cancer cell nucleus and ac-
tivate gene expression in the absence of DHT ligand [33,127,128] or (iii) activation of a
non-androgen-driven salvage pathway, as illustrated in Figure 2, but also by utilization of
the glucocorticoid receptor (GR) protein [124]. In multiple AR-expressing cell line models,
blockade of retinoic acid receptor-related orphan receptor γ (RORgamma) reduced cell
viability, by suppressing its ability to initiate AR stimulated gene expression programs in
the absence of the ligand [121,129]. The duality of control for many genes with AR and
other retinoic acid receptors [132] in prostate epithelial cells provides further evidence of a
stem-like nature of CRPC, revealed not only in gene expression and micro-RNA expression
patterns, but also provides a direct link to the single cell CRPC CTC sequencing studies
discussed earlier where genes such as WNT5A [88] and ALDH7A1, CD44 and KLF4 were
overexpressed in 60% of the heterogeneous CRPC CTC populations [65]. Alternatively,
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mutagenic changes occur in the cancer cell genome, which are irreversible and leave the
cells susceptible to further treatment strategies (see below) such as (i) specific mutations
within the AR gene to broaden the substrate choice for the receptor, (ii) amplification of the
AR gene, as seen in up to 50% of prostate cancers, as either X chromosome aneuploidy or
more commonly a tandem amplification of the AR locus (see Table 1).
5.2. Complexity and Heterogeneity: Modeling ADT in Three Dimensions
A major issue with cell line models is their inability to recapitulate the exquisite
interplay seen between the epithelial and stromal components of the human prostate. A key
role for “tumor stroma” has been proposed for many years [133–135] to affect the invasive
capacity of the epithelial component of the cancer. This is carried out by the AR-expressing
component of stroma and is therefore likely at least in non-reactive (non-tumor) stroma to
be susceptible to the inhibitory effects of anti-androgens [136]. However, the AR-induced
transcriptomes of epithelial and stromal cells are also quite distinctive [137]. Perhaps
paradoxically, recent data have implied that the effects of testosterone are repressive in
stroma (unlike epithelial cells) [138], a biological result identified by our own studies
on prostate cell recombinations in synthetic matrix [139]. There is also no doubt that
the transcriptomes seen in vitro have a number of distinct differences from those seen
in 3D tissues, mainly concerned with cell cycle (cultured cells favor growth rather than
homeostasis in tissues) and the maintenance of telomeres [140].
To model this, tissue reconstructions have been employed [141]. These do more closely
mimic responses in vivo but do require the correct constituent of matrix and stromal cells
(of an early passage in culture after surgical biopsy). More recently, this technique has
been augmented by the emergence of tissue organoids (reviewed by Wang, Gao and
Chen [142]). Single-cell expression profiling [125] identified a population of androgen-
sensitive mesenchymal/stromal cells to which was tentatively assigned a regenerative,
post-castration function to supply essential growth factors to the regenerating epithelial
cells. This inductive function is reminiscent of embryonic prostatic organogenesis [143],
where the stromal cell origin determined the ultimate differentiation of epithelial precursors
into vestigial prostate glands in my own laboratory, generation of polarized and functional
(PSA secreting) human adult glandular prostatic epithelium (from an initially AR-basal
cell population of primary human cells) which required the presence of both androgens
and androgen-sensitive stromal cells [141] to complete the process.
Organoid tools were originally designed to study self-renewal in murine and hu-
man tissue stem cells [144] and have been reported in prostate, particularly of murine
origins [145,146]. However, the efficiency of organoid generation from human prostates
is much more efficient from normal prostate and is highly selective from human prostate
cancers [145]. The underlying danger with all of these techniques is their very selectivity.
Clonality of cells in a “model system” results in more consistent data for pathway inhi-
bition, for example, but tumors (particularly prostate) are heterogeneous. Investigators
assume that the cells which grow in culture are those which drive oncogenic growth in vivo
and often erroneously assume that the majority of the cells in an organoid are those which
present the major therapeutic target. Most organoid systems also lack the in vivo input
from the carcinoma-associated fibroblasts, as described earlier. In the single-cell sequencing
experiments [125], the murine organoids generated did not include the AR-responsive
mesenchymal cells that they described. Future studies employing controlled multicellu-
lar human organoids and single-cell phenotyping after ADT in three dimensions in vitro
could resolve some of these issues, including those of mouse:human relevance and the
mechanisms of cell death and regeneration. Most importantly, even these experiments
should only provide hypotheses for subsequent testing in human tissues.
5.3. ADT in Genetically Engineered Mice
In a review of mouse models [147], the importance of selecting the most appropriate
model to answer a specific biological question was stressed. The authors concluded (like
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many before) that no model was perfect, but a recent publication which describes mice with
a multiple gene deletion core has achieved a closer concordance with human disease and
its response to androgens [148]. When these mice were castrated at 13–15 weeks and dosed
with enzalutamide for 3 weeks, the tumors did not progress over a 3–5-week period, after
which a tumor which mimics CRPC emerged and all animals died by 35 weeks (20 weeks
after treatment initiation), compared to untreated mice which died within 25 weeks. Only
limited evidence was presented on mechanisms, however.
Castration has also formed the basis for the discovery of putative luminal precursor
cells in a PTEN/KRas model of mouse prostate cancer—the (castration-resistant Nkx3.1
expressing) CARN cell [149]. The AR gene has subsequently been experimentally deleted
in this cell population [150], after which the ability of the mice to form tumors was only
somewhat compromised, and small populations of cancer cells with NE differentiation
developed, similar to those seen in a proportion of patients.
5.4. Human Xenografted Cell Models
Unlike the GEM models, which retain an intact mouse immune system, xenografted
human prostate cancer cell lines usually produce relative structureless tumors, some of
which retain expression of human AR protein [151]. A good example of an exploitable
PDX model is the PC346 androgen-responsive xenograft [152]. More commonly, cell lines
are treated in vitro with escalating doses of ADT drugs, followed by regrafting into the
murine host. The rapid growth kinetics of the cell lines in mice makes long-term castration
experiments difficult to carry out with these established tumors, which also lack the input
from human tumor stroma in most models—where the stromal component is normally
from the mouse host.
Better models which are closer to the original patients (patient-derived xenografts or
PDXs) are frequently, in their initial stages, slow growing whilst also retaining expression
of active AR [153], especially after chemical boosting of the (low) levels of circulating
androgens in the mouse host. However, it remains a challenge to establish such PDX from
hormone-naïve patients.
6. Modeling Pathway Responses to Androgen Signaling Blockade
The very nature of interlinked signaling pathways in cells, and an empirical focus
on the “expected outcome” of enzyme inhibition, can result in speculation about both
unexplained and poorly understood consequences. Figure 6 illustrates the theoretical
consequences of a blockage in the AR signaling pathway—for example, by a small molecule
(Column 1). The inhibition would result in the expected suppression of PSA expression (for
example), but also results in an accumulation of substrates before the blockade (Column 2).
The natural consequence of loss of the end product (such as PSA) from a pathway is
feedback to generate an even greater accumulation of substrates (Column 3). At this point,
most pathways activate a salvage or relief pathway to remove the unwanted excess of
signaling intermediate molecules (Column 4).
This results in the accumulation of progesterone and selection of cells containing
adaptations of the AR by mutation [154,155].
A clinical example of this is shown in Figure 7, where the testosterone biosynthetic
pathway has been effectively inhibited by abiraterone action to block CYP17 hydroxylase
and CYP17 C17, 20 lyase enzymes. Under these conditions, there is an accumulation of
pregnenolone and the pathway to aldosterone production is favored. This is in perfect
agreement with an observed escape mechanism—frequent mutation of the AR gene (T878A)
to utilize progesterone as an activator molecule [154,155]. The same mechanism can be in-
ferred for resistance to estramustine (in LNCaP cells, for example), where estrogen became
an activator of the mutated receptor (T877A) [68]. Lastly, even enzalutamide, highly engi-
neered to strongly bind to and inhibit AR protein [129], exhibits this metabolically-based
resistance, displaying a relaxation of AR substrate specificity to include glucocorticoids via
a F876L mutation [124,156]. It is not known whether subclones with such AR mutations
Cancers 2021, 13, 327 17 of 32
pre-exist in a heterogeneous tumor mass (intrinsic resistance) or are indeed induced by the
drug treatment.
 
Figure 6. Theoretical pathway inhibition after direct blockage of AR activity. Whilst most clinical emphasis is on the
downstream effects (biomarkers such as PSA) of AR inhibition (B), the accumulation of signaling molecules before the
blockade can have profound metabolic consequences (C). This is achieved not only by accumulation before the drug
blockade, but also by feedback stimulation of flow into the pathway (D). Ultimately, the excess of substrate can be relieved
in the cell by activation of a salvage pathway (E), which results in a restoration of output (PSA) by other means.
 
Figure 7. Accumulation of steroid precursors after inhibition of CYP17 by abiraterone. DHT: Dihydroteststerone, DHEA:
dehydroepiandrosterone, ACTH: Adrenocorticotropic hormone.
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However, this is a simplified scheme, as there are probably multiple and simultaneous
activations of such salvage pathways in real tumors. Artificial intelligence approaches
should permit anticipatory modeling of these alternatives, perhaps even to allow secondary
treatments.
7. Combination Drug Treatments: Is More Better?
In the ideal therapeutic strategy, the clinician would be able to anticipate the resistance
and block it by targeted combinations as and when it arises—a more dynamic form of ADT.
This probably requires a superior biomarker to PSA. However, in the case of ADT, there
are so many alternatives that, unless the resistance is corralled into a single pathway, even
combination therapies with attendant risks of off-target effects are unlikely to succeed in
the longer term. Current trials of dual AR inhibition (e.g., abiraterone plus enzalutamide),
whilst effective in the short term in the PLATO trial, showed little or no benefit for the
combined treatment of men with chemotherapy-naïve metastatic CRPC [157] and may
simply be a better way to achieve total androgen blockade, which, despite its early promise,
resulted in inevitable relapse [158,159].
Of course, a key limitation would be if different clones within the same tumor mass
activated different AR salvage pathways simultaneously upon application of ADT (induced
resistance) in genetically unstable prostate cancer cells. This would be the oncological
equivalent of fighting a wildfire, where new secondary fires are constantly being established.
Rationally, a novel approach could be to direct the resistance towards a particular pathway
and include a secondary treatment for the favored escape mechanism simultaneously with
the initial ADT.
8. Cellular Heterogeneity and Resistance to Androgen Blockade: Is Resistance
Intrinsic or Induced?
8.1. Do Prostate Cancer Stem Cells Provide a Treatment-Resistant Reservoir?
What can we ultimately learn from detailed genomic and transcriptomic studies of
CRPC in human tissues when compared to the hormone-naïve cancers from which they
are presumably derived? Unfortunately, only rarely are tumors from the same patient
subjected to such analysis, and there remains considerable doubt about just which cells
serve as the origin for CRPC [149,159–161]. Depending on the experimental system, many
explanations have been proposed, such as the following:
• trans-differentiation from an AR +/sensitive tumor cell to AR+ CRPC [161,162];
• expansion of an AR ± but androgen insensitive population of CAR cells [149]; or
• the presence of a no/low AR-expressing stem-like cell population in the primary
tumors [87,88].
The existence of this minor population of stem-like cells remains controversial. There
are many instances of identification in established cell lines, which has implied that these
rare stem-like cells are an artefact of cell culture. However, recent studies using cells
extracted directly from tissues and analyzed immediately without culture have indicated
the presence of progenitor-like cells with a unique cancer phenotype as predicted from
colony forming ability in cells from cancer tissue extracts [163]. In mice there is, as pre-
viously discussed, evidence for more luminal cells (Sections 5.1–5.3) in prostate tissue
regeneration [125,149].
The emergence of stem-like cells, with increased expression of developmentally as-
sociated regulatory pathways, has also been noted in cells resistant to enzalutamide. For
example, as discussed earlier, WNT signaling [65] is detected after ENZA treatment, and
elevated NOTCH signaling is also seen within 4 hours of the start of enzalutamide treat-
ment in vitro [64]. Rather than indicating increased cell replication, malignancy or tumor
progression, NOTCH expression may act to preserve a population of stem-like cells, as seen,
for example, after radiotherapy treatments in glioblastoma [164] and human prostate [165].
As we learn more about genomic sequences in the cancer types, and the heterogeneous
nature of even primary prostate cancers, we are less certain to conclude that a patient’s
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CRPC is the product of adaptive evolution from the originally diagnosed (and treated)
primary tumor. For example, a proportion of hormone-naive prostate cancers include
mutations in the isocitrate dehydrogenase gene (IDH1). Such mutations are, however,
absent in almost all of the CRPC tumors sequenced to date [166]. Similarly, the frequency
of the diagnostic TMPRSS2-ERG fusion in hormone-naive prostate cancers is greater than
that found in poorer prognosis and ultimately CRPC, perhaps by as much as twofold [167].
In contrast, other mutations such as PTEN deletion on chromosome 10q 21 are common
across the disease spectrum, in fact increasing in frequency in CRPC [166].
8.2. Evidence for Pre-Existing Resistant Cells in Human Clinical Trials
There has been at least one clinical trial [168] which approached the topic of pre-
existing or induced resistance in patients. In 2006, an EORTC trial (30891) reported on
outcomes of immediate or deferred hormone therapy in patients with prostate cancer
unsuitable for local treatment with curative intent. The trial outcomes are illustrated in
Figure 8.
 
Figure 8. Prior treatment with ADT in a human clinical trial does not induce resistance. In a human clinical trial [168], the
results were best explained by a selection for pre-existing resistant cells, rather than induction by the presence of the AR
inhibitor (IT = Immediate Therapy; DT = Delayed Therapy).
Significantly, in contrast to most other studies at that time, their endpoint was not
an increase in serum PSA, but rather the onset of “clinical symptoms and progression of
hormone refractory disease”. This would be less acceptable in contemporary studies, but
the use of image-driven relapse detection (in the presence/absence of increased PSA) could
now offer similar outcome data to update this study. Even with a relatively imprecise means
of determining clinical relapse, remarkable overlap in the relapse curves was observed in
a trial of 985 randomized patients comparing immediate vs. deferred ADT. The data did
reveal a modest (10%) survival advantage for immediate hormone treatment (compared to
delayed) over the 11-year follow-up (225/492 vs. 209/493). Were the immediate application
of AR therapies inducing a new cell population, one would expect a more rapid relapse
rate upon treatment failure, due to an increased frequency over the time of treatment, of
resistant cell clones in the cancer. The close coincidence of the relapse curves does imply the
presence of a pre-existing resistant population, acting as the “seed” for relapse. Similarly,
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it has been possible to detect small “nests” of cells with AR copy number increases in
hormone-naïve prostate cancers in the absence of any ADT induction [30].
Although beyond the scope of this review, the origins of CRPC relapse towards, for
example, a neuroendocrine phenotype, which is now more common as a result of secondary
ADT, are also open to speculation.
As illustrated in Figure 9, the hypothesis of an adaptation (or dedifferentiation) of a
CRPC phenotype to neuroendocrine-like tumors has been proposed in both patients and in
animal models [160,169]. Rare NE-like cells exist in normal prostate [170], although recently,
their origin in normal mouse prostate gland development has been suggested to be the
neural crest, instead of a common prostate precursor cell [171]. Minor populations of rare
NE tumor cells are also seen in HDT-naïve cancer tissue sections [170] amidst the hormone-
responsive tumor mass, increasing in number upon development of CRPC. However, the
mutational profiles do not exclude the presence of rare, treatment-resistant, pre-existing,
less differentiated cells, which can amplify and aberrantly differentiate to generate both the
neuroendocrine-like cancers and more common glandular CRPC [126]. However, NE-like
cells can be generated by epigenetic manipulation of normal and malignant epithelial cells,
whose markers of origin they retain, so there is a developmental precedent as well as an
invocation of a novel trans-differentiation process. A resolution of this would pave the way
for a better treatment of the currently treatment refractory NE tumor types.
 
Figure 9. Models for development of castration-resistant prostate cancers. Upper Panel: In a trans- or dedifferentiation
model of resistance, the tumor cells are growth arrested by the presence of the AR inhibition. During growth arrest, the
tumor cells have a genetic plasticity which pushes tumor cells towards a drug-resistant phenotype by the presence of the
drug. Most tumor cells can therefore be the progenitors for the resistant (CRPC) tumor, and the CRPC cells will share most
if not all of the mutations in the original bulk tumor cells. Lower Panel: In a hierarchical or stem cell model of resistance,
there is a small population of relatively undifferentiated (or stem-like) cells present in every tumor, which contain cancer
driver mutations. Under selective pressure from an anti-AR drug, which arrests the growth of the bulk cancer cells, variants
can emerge from the common pre-existing precursor which develop new adaptive mutations. Assuming that the original
bulk cancers had developed adaptive mutations from their underlying progenitors, the resultant CRPC cells should share
only the driver mutations with the original cancers and have a new set of changes for growth under ADT conditions.
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9. Modeling Pathways to CRPC—Predictions from Mechanism Testing
Without the ability to study human tumor development in vivo (in real time), it will
remain almost impossible to distinguish between the two most credible alternative mecha-
nisms which result in castration-resistant disease (Figure 8), i.e., stochastic or hierarchical
changes. Perhaps the best resolution of the alternatives will lie in the use of selective
inhibitors. The process of trans-differentiation from a luminal-like cell to CRPC will almost
certainly require activation of a different geneset from a more conventional or stalled
differentiation of a stem-like androgen-insensitive (basal-like) precursor to the stem-like
phenotype of CRPC. However, we should remember that the starting cell type from which
CRPC derives is a tumor cell, with known phenotypic plasticity and an underlying number
of patient-specific variable driver gene changes [172] required to achieve a tumor pheno-
type from a normal/premalignant precursor. It has proved difficult to extract a “standard”
tumor phenotype from current prostate cancer gene expression databases [166].
10. Does Better Androgen Blockade Change the Natural History of Prostate Cancer?
10.1. Long-Term Effects of Low Androgen Levels in Men with Benign and Malignant
Prostate Disease
Hundreds of thousands of men are treated every year with increasingly potent ADT
drugs, all designed to block the androgen signaling axis in prostate cancer cells. The clinical
effects are immediate, the biomarkers (PSA, for example) are easily monitored and tumor
masses are reduced—albeit by an undetermined mechanism. ADT is a major healthcare
expenditure, but we still do not know at a molecular level the short term, or even more
significantly, the longer-term effects of persistently low levels of AR signaling in men. As
stronger ADT is applied more generally and perhaps even at an earlier disease stage in
more men, the adverse effects may become more apparent—but are these valid in the face
of evidence of increased short-term efficacies? For example, does long-term application
of ADT result in a change in the natural history of prostate cancer—for example, more
small-cell basal-like and neuroendocrine tumors [173], which are notoriously difficult to
treat? Changes in the locations and types of ADT-resistant metastases are also emerging,
where “soft tissue” lesions are increasing in prevalence [174].
As discussed above, the low levels of cell death after ADT in patients, and the persis-
tence of viable ADT-resistant cells rather than their elimination, provides the ideal breeding
ground/selection system for variant development. We know that this happens, since CRPC
will develop in the majority of patients—we just do not know how it happens [126,160–162].
Therefore, does the strategy of generating new ADT agents and a focus on the sequenc-
ing of the various blockades of the AR signaling pathway offer patients the best chance
of long-term treatment? The cycling of ADT [15,175], and/or the perhaps anti-intuitive
approach of overstimulation of the AR pathway [176,177], offer a remission but, never-
theless, temporary survival advantages. Application of ADT does offer an opportunity
for more curative combinations of treatment, however. The achievement of growth arrest
and regrowth in a cyclic application would seem to offer the best opportunity to eliminate
minor resistant populations.
10.2. Androgens Are Not Just Active in Male Reproductive Organs: Extra-Prostatic Effects of
Long-Term ADT
As a male reproductive organ, the high level of expression of the AR in cells from
the prostate and its disorders, such as benign prostatic hyperplasia (BPH), prostatic in-
traepithelial neoplasia (PIN) and prostate cancer, is not a surprising experimental result.
However, AR expression is not restricted to the secretory, epithelial component of prostate
tissues [178]. Conversely, there are epithelial cells in prostate which do not express detectable
AR protein [179]. In mouse prostate development, it is the androgen response not of the
epithelial component but of the stromal cells which promotes initial prostate epithelial differ-
entiation and organogenesis [180], as shown in the embryonic mesenchymal+epithelial cell
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mixture experiments of Cunha et al. [143], which clearly showed that the embryonic fate of
the epithelial cells was largely determined by AR-driven stromal signals.
Therefore, androgen response inhibition in man should effectively limit the growth
and development of the prostate and testes as a minimum, but is this a truly tissue-
targeted therapy? The 5-alpha reductase inhibitors such as dutasteride or finasteride
showed variable efficacy as either chemopreventive or treatment agents for prostate cancer—
revealed in a much-debated enhanced detection of high Gleason score cancers in the
PCPT trial [26], whilst apparently suppressing low-grade cancers [181]. More recent
studies [182] have reinforced the positive aspects of the PCPT trial output, although we
remain naïve about the best time and age to apply such therapies in men. The perceived
adverse effects resulted in the rejection of 5-alpha reductase inhibitors by the FDA in
a chemoprevention role for prostate cancer, and similar studies with the dual-action 5-
alpha reductase inhibitor Dutasteride in the subsequent REDUCE trial failed to show any
effect on more aggressive tumors whilst shrinking lower grade or faster growing cancers
(summarized by Schroder and Roobol [183]). Hormonal interventions in most Gleason
score 6 and lower cancers, when organ confined, may even be unnecessary, given the data
from recent active surveillance trials such as PROTECT [184].
However, one interesting “off-target effect” of 5-alpha reductase inhibition (e.g., with
Propecia) has been hair regrowth in cases of male pattern baldness, resulting in a re-
purposing of the latter drugs by the manufacturers. However, such long-term use of
hormone activity manipulators seems to be having undesirable effects in a number of
health areas, including but not limited to libido [185]: around 15,000 post-finasteride
adverse effects at a clinically relevant level have been reported to an online forum (pfs-
foundation.org), perhaps implying a more widespread relevance of androgen signaling in
man than just in the prostate, although the recent re-evaluation of the PCPT trial largely
refuted a finasteride-based mechanism for these effects [182]. As the number of patients on
long-term maintenance of prostate cancer remission with ADT increases, more evidence
accumulates about potential physical effects of androgen suppression, including decreases
in bone mineral density, metabolic changes such as weight gain, decreased muscle mass,
and increased insulin resistance, decreased libido and sexual dysfunction, hot flashes,
gynecomastia, reduced testicle size, anemia, and fatigue [186].
An increase in cardiovascular events has been frequently noted, but statistically, the
evidence for this remains marginal [187], although increased death due to cardiovascular
events is regularly observed.
Adverse effects on animal brain development with finasteride treatment have recently
been reported in rat brains [188] and, as summarized in Figure 10, active AR signaling
(indicated by high levels of the protein in the cell nuclei) has been observed, for example,
in the brain [189]. A more widespread distribution of AR mRNA and protein is recorded in
the online gene expression databases. Whilst strong expression is indeed seen in the male
reproductive tract, similarly strong expression of AR protein in the cell nucleus was more
markedly detected in bone marrow, spleen and thymus [178,190]. There are currently a
number of (tissue) selective androgen receptor modifiers (SARMs) available [191]. Is it too
great a leap of faith or chemistry to redesign these tissue-specific reagents as inhibitors?
Exploitation of tissue-targeting SARMs could also provide the advantages of AR sup-
plementation to muscle-wasting diseases and immune depletion in patients undergoing
treatment with the current AR inhibitors.
Most current and next-generation AR inhibitors can cross the blood–brain barrier
(with the reported exception of Darolutamide (Bayer) which is currently in clinical trials
(ARAMIS [192]), but whether brain expression of AR is directly linked to observed seizures,
as an adverse effect of therapy, remains unproven [193].
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Figure 10. Expression patterns of human androgen receptor in multiple and non-prostatic tissue data from Dart et al. [178]
and other sources in text.
In the immune regulatory tissues, it is credible to expect that the cytoproliferative and
protective effects of AR expression would be immune-stimulatory and that the observed
depletion of such responses could provide an alternative explanation for the relatively poor
responses of patients to prostate immunotherapy, since most such treatments are being
employed after failure of ADT [194]. Paradoxically, however, in castrated (or AR knockout)
rodents, the size of the thymus actually increases and is reduced by the inoculation of
testosterone [190]. Indeed, given such widespread expression of the target (AR) molecule,
it might be questioned whether androgen receptor inhibition would today be licensed de
novo for use in any but the most terminally ill cancer patients!
11. Future Perspectives: Exploiting Mechanistic Biology for Patient Advantage in
An-drogen-Based Therapies
If we accept that the effects of ADT in man do differ from those in animal models
and in vitro cultures, longer-term and precise monitoring studies during clinical trials
will be required to unlock the resistance mechanisms. The advent of single-cell gene
expression analysis is likely to identify better secondary targets than more detailed genomic
sequencing, as there is increasing evidence that the first responses of human cancer cells
to therapy are at an epigenetic level, in, for example, pancreatic cancers [195]—a lower
mutation cancer type, similar to pre-ADT prostate cancers. The presence of higher numbers
of mutations in CRPC tissues at autopsy is probably indicative of developmental changes
as the tumor grows to a final fatal form. As discussed above, “prostate cancer” and “CRPC”
are both generic terms describing a tumor state, which can be achieved by many pathways.
Single-cell sequencing, just like the multiple mechanisms of resistance to ADT, provides
the best case for stratified or even patient-specific treatments based on individual tumor
genome/epigenomes. However, which cells should be sequenced? I would promote
analysis of ALL viable cells ahead of recognizable “prostate” or “epithelial cells”, all too
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frequently based on AR expression. To reject a cell phenotype which does not confirm to an
expected type might result in the exclusion of a rare precursor of treatment failure—a lesson
to be learned from studies of fetal brains and brain tumors, where “new” cell subtypes can
be recognized after single-cell expression profiling [196].
12. Conclusions
Identification of the prostate tissue cells in which ADT stimulates regenerative gene
expression, whether normal or malignant, should be a priority in order to make a very
good time-limited palliative treatment into an excellent curative one. The keys to achieving
lasting benefits from ADT lie in the prompt identification and blockade of the secondary
pathways by a directed combination therapy, before a resistant clone of new tumor cells
emerges either by a trans-differentiation /selection or from a pre-existing pool of resistant
stem-like cells, for example. With the current evidence, I am unable to answer the question
posed in my title—there is evidence for both pre-existing and induced resistance, although
the results are critically dependent on the model used for study. However, even the state of
the art in hormonal therapy is time-limited and resistance does indeed seem inevitable.
Androgen-based therapies are not inevitably doomed to failure: they are highly
effective in the short term. Perhaps exploitation of the range of agents now available in
a more biologically determined fashion would offer better long-term outcomes for more
prostate cancer patients.
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